Advances in treatment of chronic lymphocytic leukemia / 白血病·淋巴瘤

ABSTRACT

Great advances have been made recently in the therapy of chronic lymphocytic leukemia due mainly to the application of novel agents. In the 58th American Society of Hematology Annual Meeting, the latest outcomes of many clinical studies have been reported. The present article will review the reports and focus on the following studies on chronic lymphocytic leukemia (CLL): the long-term therapeutic outcome of BTKi and the result of combination therapy of BTKi with other agents; the short-term result of bcl-2 inhibitor in CLL; the efficacy of maintenance therapy with lenalidomide in CLL patients; CD19-CAR T-cell therapy achieved good response. Traditional immunochemotherapy with combination of fludarabine, cyclophosphamide and rituximab is still the first-line option for fit patients through long-term follow-up. The allogeneic stem cell transplantation remains a curative strategy for CLL but with stricter indication.